These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 10757031)

  • 1. Therapy burden, drug resistance, and optimal treatment regimen for cancer chemotherapy.
    Boldrini JL; Costa MI
    IMA J Math Appl Med Biol; 2000 Mar; 17(1):33-51. PubMed ID: 10757031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dosage regimen optimization in cancer chemotherapy using a mathematical model].
    Barbolosi D; Freyer G; Ciccolini J; Iliadis A
    Bull Cancer; 2003 Feb; 90(2):167-75. PubMed ID: 12660135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Some drug-resistant models for cancer chemotherapy. Part 1: Cycle-nonspecific drugs.
    Usher JR; Henderson D
    IMA J Math Appl Med Biol; 1996 Jun; 13(2):99-126. PubMed ID: 8671582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing drug regimens in cancer chemotherapy by an efficacy-toxicity mathematical model.
    Iliadis A; Barbolosi D
    Comput Biomed Res; 2000 Jun; 33(3):211-26. PubMed ID: 10860586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal chemotherapy regimens: influence of tumours on normal cells and several toxicity constraints.
    Matveev AS; Savkin AV
    IMA J Math Appl Med Biol; 2001 Mar; 18(1):25-40. PubMed ID: 11339336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy for tumors: an analysis of the dynamics and a study of quadratic and linear optimal controls.
    de Pillis LG; Gu W; Fister KR; Head T; Maples K; Murugan A; Neal T; Yoshida K
    Math Biosci; 2007 Sep; 209(1):292-315. PubMed ID: 17306310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of tumours on normal cells and optimal chemotherapy regimens: the case of several drugs and toxicity constraints.
    Matveev AS; Savkin AV
    Math Med Biol; 2005 Jun; 22(2):143-62. PubMed ID: 15781427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current clinical and research approaches to optimizing regional chemotherapy: novel strategies generated through a better understanding of drug pharmacokinetics, drug resistance, and the development of clinically relevant animal models.
    Beasley GM; Kahn L; Tyler DS
    Surg Oncol Clin N Am; 2008 Oct; 17(4):731-58, vii-viii. PubMed ID: 18722915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
    Deisseroth AB; DeVita VT
    Cancer J Sci Am; 1995; 1(1):15-21. PubMed ID: 9166447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy may be delivered based on an integrated view of tumour dynamics.
    Ribba B; You B; Tod M; Girard P; Tranchand B; Trillet-Lenoir V; Freyer G
    IET Syst Biol; 2009 May; 3(3):180-90. PubMed ID: 19449978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
    Shah MA; Schwartz GK
    Clin Cancer Res; 2001 Aug; 7(8):2168-81. PubMed ID: 11489790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence and prevention of resistance against small molecule inhibitors.
    Wodarz D; Komarova NL
    Semin Cancer Biol; 2005 Dec; 15(6):506-14. PubMed ID: 16154360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug delivery to tumours: recent strategies.
    Reddy LH
    J Pharm Pharmacol; 2005 Oct; 57(10):1231-42. PubMed ID: 16259751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling oxaliplatin drug delivery to circadian rhythms in drug metabolism and host tolerance.
    Clairambault J
    Adv Drug Deliv Rev; 2007 Aug; 59(9-10):1054-68. PubMed ID: 17707544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell resensitization after delivery of a cycle-specific anticancer drug and effect of dose splitting: learning from tumour cords.
    Bertuzzi A; Fasano A; Gandolfi A; Sinisgalli C
    J Theor Biol; 2007 Feb; 244(3):388-99. PubMed ID: 17074361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The optimal scheduling of two drugs with simple resistance for a problem in cancer chemotherapy.
    Murray JM
    IMA J Math Appl Med Biol; 1997 Dec; 14(4):283-303. PubMed ID: 9415996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal controls for a model with pharmacokinetics maximizing bone marrow in cancer chemotherapy.
    Ledzewicz U; Schättler H
    Math Biosci; 2007 Apr; 206(2):320-42. PubMed ID: 16197967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling chemotherapy resistance in palliation and failed cure.
    Monro HC; Gaffney EA
    J Theor Biol; 2009 Mar; 257(2):292-302. PubMed ID: 19135065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.